CITC 2024 – D1S04 – Q&A Discussion Panel 1

CITC 2024 – D1S02 – Basics of Clinical Trial Design

CITC 2024 – D1S05 – Safety Considerations in Clinical Drug Development

FDA Expert Panel on Testosterone Replacement Therapy for Men

A Deep Dive: FDA’s Model-Integrated Evidence (MIE) Industry Meeting Pilot Program for Generic Drugs

CITC 2024 – D3S08 – Q&A Discussion Panel 2

FDA Grand Rounds - Adopting Large Language Models for Regulatory Review

Roundtable on PMTA Submissions for ENDS Products

FDA Grand Rounds - Antibody Glycosylation Insights for High Quality Biotherapeutics

FDA Grand Rounds - Advancing Real World Evidence in FDA Regulatory Decision Making

FDA Grand Rounds - Statistical Considerations for Drug Development in Rare Disease

FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

FDA Grand Rounds - Postmarket Regulation of Cosmetic Products: The Who, What, When, Why, and How

Medical Device Quality Management System Regulation Design and Development

FDA Grand Rounds - Forensic Proteomics Applied to FDA Regulated Products

Public Meeting: Reauthorization of the Biosimilar User Fee Act

FDA-USP-AAM | D1S4 – Q&A Discussion Panel

FDA's Public Meeting on Food Allergen Thresholds - 02/18/2026

FDA Grand Rounds - Anti biofilm Technologies for Enhancing the Safety of Medical Device Surfaces

FDA-USP-AAM | D1S1 – FDA's Participation in USP-NF Revision Process – Challenges and Solutions